Clinical guidelines

The Therapeutic Goods Administration (TGA), with the support of the NSW, Victorian and Queensland state governments, commissioned a team to review the available scientific evidence for the use of cannabis medicines in five areas: palliative care, nausea and vomiting, epilepsy, multiple sclerosis and pain.

The NSW Government supported the review to provide a source of credible information about the available evidence to support medical practitioners considering the use of a cannabis medicine for their patient.

Advice developed for medical practitioners includes: